Scientific article

Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study

Published inAntiviral therapy, vol. 11, no. 2, p. 131-142
Publication date2006

BACKGROUND: Morbidity and mortality of individuals co-infected with HIV and hepatitis C virus (HCV) is often determined by the course of their HCV infection. Only a selected proportion of those in need of HCV treatment are studied in randomized controlled trials (RCTs). We analysed the prevalence of HCV infection in a large cohort, the number of individuals requiring treatment, the eligibility for HCV treatment, and the outcome of the combination therapy with pegylated interferon-a and ribavirin in routine practice. METHODS: We analysed prescription patterns of HCV treatment and treatment outcomes among participants from the Swiss HIV Cohort Study with detectable hepatitis C viraemia (between January 2001 and October 2004). Efficacy was measured by the number of patients with undetectable HCV RNA at the end of therapy (EOTR) and at 6 months after treatment termination (SVR). Intention-to-continue-treatment principles were used. RESULTS: A total of 2150 of 7048 (30.5%) participants were coinfected with HCV; HCV RNA was detected in 60%, and not assessed in 26% of HCV-antibody-positive individuals. One hundred and sixty (12.5%) of HCV-RNA-positive patients started treatment. In patients infected with HCV genotypes 1/4 or 2/3, EOTR was achieved in 43.3% and 81.2% of patients, respectively, and SVR rates were 28.4% and 51.8%, respectively. More than 50% of the HCV-treated patients would have been excluded from two large published RCTs due to demographic, clinical and laboratory criteria. CONCLUSIONS: Despite clinical and psychosocial obstacles encountered in clinical practice, HCV treatment in HIV-coinfected individuals is feasible with results similar to those obtained in RCTs.

  • Adult
  • Antiviral Agents/ therapeutic use
  • Cohort Studies
  • Female
  • HIV Infections/ complications
  • Hepatitis C/ complications/ drug therapy/virology
  • Hepatitis C Antibodies/blood
  • Humans
  • Interferon Alfa-2a/therapeutic use
  • Interferon Alfa-2b/therapeutic use
  • Male
  • Middle Aged
  • Polyethylene Glycols/therapeutic use
  • RNA, Viral/blood
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Ribavirin/therapeutic use
  • Switzerland
Citation (ISO format)
ZINKERNAGEL, A. S. et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. In: Antiviral therapy, 2006, vol. 11, n° 2, p. 131–142.
Updates (1)
ISSN of the journal1359-6535

Technical informations

Creation06/21/2010 10:27:19 AM
First validation06/21/2010 10:27:19 AM
Update time03/14/2023 3:46:23 PM
Status update03/14/2023 3:46:23 PM
Last indexation08/28/2023 6:22:54 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack